查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004827

介入性神經外科醫療設備市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Interventional Neurology Devices Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，介入性神經醫療設備市場價值將達到 23.8 億美元，到 2026 年將成長至 26.2 億美元，到 2032 年將達到 44.8 億美元，複合年成長率為 9.44%。

主要市場統計數據
基準年 2025 23.8億美元
預計年份：2026年 26.2億美元
預測年份 2032 44.8億美元
複合年成長率 (%) 9.44%

這本權威的入門書籍說明了設備類別、臨床應用和操作技術與現代護理路徑和相關人員決策標準之間的關係。

介入性神經外科器械處於快速臨床創新和不斷發展的醫療服務流程的交匯點，這不僅為臨床醫生、醫院管理者和醫療技術開發人員帶來了機遇，也帶來了挑戰。本報告首先概述了關鍵器械類別及其臨床應用和手術流程，然後建立了一個框架，闡述如何將各項技術整合到腦血管疾病的治療流程中。報告強調了器械的連續性，從栓塞器和血流灌注系統到先進的彈簧圈、支架和血栓切除平台，並說明如何在手術團隊和影像環境中最佳化這些器械的使用。

設備創新、臨床證據的成熟以及醫療保健服務體系的重組，是如何重新定義神經血管照護的治療方法和實施趨勢的？

由於技術進步、臨床證據日趨成熟以及醫療服務模式的重組，介入神經病學領域正經歷變革性的轉變。近年來，血流灌注平台的進步，以及線圈配置和支架設計的不斷改進，重新定義了複雜動脈瘤的治療閾值，並擴大了血管內治療的選擇範圍。同時，血栓除去裝置的改進，特別是抽吸導管和血栓摘取支架的改進，提高了急性缺血性腦中風的治療標準。手術流程的改進體現在器械設計、導管相容性以及輔助系統的整合等方面。

本研究評估了近期關稅變化和貿易政策轉變對醫療設備供應鏈和醫院採購行為的廣泛運作、採購和購買影響。

美國政策的轉變和關稅調整正對介入性神經病學器械生態系統產生重大影響，波及供應鏈經濟、籌資策略和國際採購決策。某些醫療設備組件和原料關稅的提高，增加了依賴跨境供應鏈的製造商的投入成本。這種壓力促使企業更加嚴格地審查供應商契約，加快供應商多元化策略的實施，並重新評估庫存管理實踐，以降低貿易相關的成本波動風險。

將產品差異化、臨床應用需求、技術基礎和最終用戶優先事項與部署和商業化方案連結起來的實用細分見解。

精細化的細分觀點揭示了不同產品類型、臨床應用、技術平台和終端用戶環境之間的差異，這些差異共同塑造了醫療設備製造商和醫療保健系統的策略重點。在產品類型中，創新路徑也各不相同。栓塞劑正朝向液體栓塞劑、微球和顆粒劑等多種方向發展，以實現個人化的栓塞方案。同時，血流導向裝置也不斷演進，形成諸如Fred、Pipeline裝置和Surpass Streamline等差異化平台，每種平台在輸送能力和孔隙率方面都存在差異。神經血管彈簧圈的材料也日益多樣化，生物活性彈簧圈和水凝膠增強彈簧圈與傳統的鉑金彈簧圈相比，能夠提供不同的癒合反應。支架結構也朝著球囊擴張型和自擴張式設計發展，以適應不同的解剖結構和手術操作。從操作角度來看，血栓除去裝置可分為抽吸導管系統和血栓摘取支架，每種類型都會影響手術流程和影像需求。

區域法規結構、臨床基礎設施成熟度和製造生態系統如何塑造全球主要市場中差異化的部署模式？

區域趨勢對器材研發、監管策略和臨床應用模式有著顯著影響，美洲、歐洲、中東、非洲和亞太地區呈現出各自獨特的市場促進因素。在美洲，完善的急性卒中診療網路、先進的影像基礎設施以及集中於綜合醫療體系中的強大採購能力，正在加速最先進的血栓切除術和血流逆轉器械的應用；同時，供應鏈因素和報銷環境也影響著採購週期和應用速度。該地區的臨床研究網路和註冊登記系統有助於快速產生循證醫學證據，從而支持器械的迭代改進和指南的納入。

以整合平台、證據產生和協作商業化為優先的策略性企業行動和競爭定位，以推動永續的臨床應用。

介入性神經病學領域的競爭動態取決於對研發的持續投入、策略夥伴關係以及以臨床實踐為導向的項目，這些因素共同推動了產品差異化和平台演進。主要企業大力投資於最佳化器械輸送性能、材料科學和平台互通性，同時積極開展有針對性的臨床研究和真實世界數據（REW）項目，以支持其性能聲明。與學術機構和神經血管註冊中心的合作能夠提供關鍵數據，支持擴大適應症範圍和指南採納，從而增強臨床醫生的信心並提升醫院採購委員會的評估水平。

為製造商、醫療保健系統和臨床領導者提供切實可行的優先建議，以協調證據、供應彈性和商業化，從而實現永續應用。

行業領導者應優先考慮一系列務實舉措，使產品開發、商業性合作和營運韌性與不斷變化的臨床和政策現實相契合。首先，應投資建立健全的臨床證據項目，涵蓋縱向結果、病患報告結果和衛生經濟學分析，這些分析應能引起醫院負責人和支付方決策者的共鳴，而不僅限於急性治療指標。此外，還應利用可操作的註冊數據和真實世界績效報告來補充臨床試驗，從而加速指南的採納和支付方的核准。

混合方法研究框架，結合臨床醫生和採購負責人的初步見解與系統的二次分析，得出穩健且可重複的結論。

本研究將採用混合方法，以與關鍵相關人員的互動和嚴謹的二手資料研究為核心，整合多方面的證據，建構神經介入醫療設備環境的全面圖景。主要資訊來源包括對臨床意見領袖、介入醫師、醫院採購經理和醫療設備研發專家的資訊來源，以獲取關於手術趨勢、醫療設備性能預期和醫療保健優先事項的第一手觀點。此外，還將收集來自手術團隊的匿名調查數據，檢驗不同醫療機構中醫療設備的選擇模式和使用趨勢，從而補充上述定性研究。

對臨床、營運和政策趨勢進行簡潔、全面的分析，重點在於加速設備普及和維持臨床影響的統一優先事項。

總而言之，介入性神經外科器械正處於臨床創新、供應鏈複雜性和醫療服務模式變革的快速交匯點，所有這些因素共同決定了製造商、醫療服務提供者和支付方的策略重點。從栓塞劑和彈簧圈材料到先進的血流導引平台和血栓切除系統，器械的發展軌跡表明，材料科學、器械工程和手術流程如何協同演進，以改善患者預後。同時，貿易政策趨勢和關稅相關壓力凸顯了具有韌性的籌資策略和靈活的商業性安排的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 介入性神經醫療設備市場：依產品類型分類

  • 栓塞劑
    • 液態栓塞劑
    • 微球
    • 顆粒栓子
  • 血液灌流裝置
    • Fred
    • 管道裝置
    • 超越流線型
  • 神經血管線圈
    • 生物活性線圈
    • 水凝膠線圈
    • 鉑金線圈
  • 神經血管支架
    • 球囊擴張型支架
    • 自動擴張型支架
  • 血栓除去裝置
    • 吸痰管
    • 血栓摘取支架

第9章 介入性神經醫療設備市場：依技術分類

  • 導管導引線系統
    • 親水塗層
    • 聚合物塗層
  • 機械血栓切除術
  • 微導管系統
    • 導絲引導式微導管
    • 快速交換微導管
  • 溶栓劑
    • tpa
    • 尿激酶

第10章 介入性神經醫療設備市場：依應用領域分類

  • 動脈瘤
  • 動靜脈畸形
  • 頸動脈狹窄
  • 缺血性中風
  • 血管痙攣

第11章 介入性神經醫療設備市場：依最終用戶分類

  • 門診手術中心
  • 診斷影像中心
  • 醫院
  • 介入神經放射學診所

第12章 介入性神經醫療設備市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 介入性神經醫療設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 介入性神經醫療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國介入性神經醫療設備市場

第16章：中國介入神經醫療設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acandis GmbH
  • B. Braun Melsungen AG
  • Balt USA LLC
  • Boston Scientific Corporation
  • Cerus Endovascular Ltd.
  • Integer Holdings Corporation
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson Services, Inc.
  • Medos SA
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • MicroVention, Inc.
  • Penumbra, Inc.
  • Rapid Medical
  • Stryker Corporation
  • Terumo Corporation
Product Code: MRR-742BD517FEBA

The Interventional Neurology Devices Market was valued at USD 2.38 billion in 2025 and is projected to grow to USD 2.62 billion in 2026, with a CAGR of 9.44%, reaching USD 4.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.38 billion
Estimated Year [2026] USD 2.62 billion
Forecast Year [2032] USD 4.48 billion
CAGR (%) 9.44%

An authoritative introduction that maps device categories, clinical applications, and procedural technologies to contemporary care pathways and stakeholder decision criteria

Interventional neurology devices are at the intersection of rapid clinical innovation and evolving care delivery pathways, creating both opportunity and complexity for clinicians, hospital administrators, and medical technology developers. This report initiates with a focused overview that situates core device categories alongside clinical applications and procedural workflows, framing how distinct technologies integrate into treatment algorithms for cerebrovascular disease. Emphasis is placed on the continuum of devices, from embolic agents and flow diversion systems to advanced coils, stents, and thrombectomy platforms, and how these instruments are optimized within procedural teams and imaging environments.

In parallel, the introduction outlines how device-specific innovations such as liquid embolics, microspheres, and particulate embolics have influenced therapeutic choices for aneurysm and arteriovenous malformation interventions, while flow diversion devices including high-profile platforms have altered the approach to complex aneurysm management. The narrative also recognizes the differential roles of neurovascular coils-ranging from bioactive and hydrogel variants to traditional platinum coils-and the technical distinctions between balloon-expandable and self-expanding stent designs. The thrombectomy armamentarium, including aspiration catheters and stent retrievers, is positioned within acute ischemic stroke pathways, underscoring the time-sensitive nature of device performance.

Finally, the introductory section sets expectations for the report's analytical scope by describing how device categories interact with application areas such as aneurysm, arteriovenous malformations, carotid stenosis, ischemic stroke, and vasospasm. It explains how advances in guidewire systems, microcatheter platforms, mechanical thrombectomy techniques, and thrombolytic agents underpin procedural success, and how end users across ambulatory surgical centers, diagnostic imaging centers, hospitals, and specialized neuro interventional clinics shape adoption dynamics. This framing prepares readers for detailed downstream analysis of regulatory, clinical, economic, and operational factors that drive strategic choices across the ecosystem.

How converging device innovation, clinical evidence maturation, and care-delivery reconfiguration are redefining therapeutic approaches and adoption dynamics across neurovascular practice

The interventional neurology landscape is undergoing transformative shifts driven by converging technological advancements, clinical evidence maturation, and reconfigured care delivery models. Over recent years, the increasing refinement of flow diversion platforms-alongside iterative improvements in coil composition and stent design-has redefined therapeutic thresholds for complex aneurysms and expanded endovascular options. Concurrent enhancements in thrombectomy devices, specifically aspiration catheters and stent retrievers, have elevated the standard of care in acute ischemic stroke, with procedural refinements reflected in device design, catheter compatibility, and ancillary system integration.

Technological progress is complemented by advances in supporting systems such as guidewire variants with hydrophilic or polymer coatings, refined microcatheter architectures including over-the-wire and rapid-exchange designs, and evolving thrombolytic agents like tPA and urokinase that influence adjunctive strategies. These innovations are reshaping procedural workflows and prompting multidisciplinary teams to reassess training, imaging protocols, and peri-procedural care. Meanwhile, adoption patterns are shifting as care migrates beyond traditional hospital interventional suites to ambulatory surgical centers and specialized neuro interventional clinics that prioritize throughput, patient experience, and cost optimization.

Regulatory landscapes and payer policies are adapting to new evidence and real-world data collection, catalyzing a stronger focus on value demonstration and longitudinal outcomes. At the same time, manufacturers are pursuing portfolio consolidation and modular platform strategies to provide end-to-end procedural solutions. Taken together, these forces are producing a dynamic environment in which clinical efficacy, device interoperability, and care-delivery economics jointly determine successful product adoption and long-term clinical integration.

Evaluating the broad operational, sourcing, and procurement consequences of recent tariff changes and trade policy shifts on device supply chains and hospital purchasing behaviors

Policy shifts and tariff adjustments in the United States have material implications for the interventional neurology device ecosystem, impacting supply chain economics, procurement strategies, and international sourcing decisions. Increased tariffs on certain medical device components and raw materials elevate input costs for manufacturers who depend on cross-border supply chains. This pressure translates into heightened scrutiny of supplier contracts, an acceleration of supplier diversification strategies, and a reassessment of inventory management practices to mitigate exposure to trade-related cost volatility.

Manufacturers and distributors respond by accelerating localization and nearshoring initiatives where feasible, expanding dual-sourcing arrangements, and renegotiating commercial terms to preserve margins while maintaining competitive pricing for hospitals and imaging centers. Hospitals and ambulatory surgical centers, mindful of constrained budgets, intensify procurement diligence and prioritize devices supported by robust clinical data and predictable lifecycle costs. As a result, there is increased emphasis on total cost of ownership analyses, long-term service agreements, and arrangements that bundle consumables with device platforms to achieve price stability.

Clinicians and hospital administrators also adjust procurement timelines and capital planning to accommodate lead-time variability and potential tariff-related cost adjustments. Regulatory and compliance teams must remain vigilant to ensure that device modifications or supplier changes do not inadvertently affect regulatory status or clinical labeling. Finally, payers and health systems may scrutinize unit pricing and reimbursement pathways more closely, driving manufacturers to emphasize outcomes-based evidence and align commercial models with performance metrics that resonate with value-driven stakeholders.

Actionable segmentation insights that connect product differentiation, clinical application demands, technology enablers, and end-user priorities to implementation and commercialization choices

A granular segmentation lens reveals distinct dynamics across product types, clinical applications, technology platforms, and end-user settings that collectively shape strategic priorities for device manufacturers and health systems. Within product categories, differential innovation trajectories are evident: embolic agents have diversified into liquid embolics, microspheres, and particulate options that enable tailored embolization profiles, while flow diversion devices have evolved into differentiated platforms such as Fred, Pipeline devices, and Surpass streamlines that vary in deliverability and porosity. Neurovascular coils demonstrate material-driven differentiation with bioactive and hydrogel-enhanced coils offering distinct healing responses compared with traditional platinum coils, and stent architectures split between balloon-expandable and self-expanding designs to accommodate anatomical and procedural variability. Thrombectomy devices divide operationally between aspiration catheter systems and stent retrievers, each influencing procedural workflow and imaging requirements.

Application-based segmentation highlights how device choice aligns tightly to clinical goals. Aneurysm treatment prioritizes device conformability and long-term vessel remodeling, arteriovenous malformation interventions require precise embolic control, carotid stenosis management balances hemodynamic restoration with embolic protection, ischemic stroke care is dominated by time-to-revascularization imperatives, and vasospasm therapies emphasize targeted delivery and vessel-sparing profiles. Technology segmentation underscores the role of ancillary systems in enabling successful procedures: guidewire systems with hydrophilic or polymer coatings affect maneuverability, mechanical thrombectomy techniques demand compatible catheter and stent designs, microcatheter system variations influence crossing strategies and device deployment options, and thrombolytic agents such as tPA and urokinase remain central to adjunctive pharmacologic protocols.

End-user segmentation illuminates the influence of care settings on device adoption and utilization patterns. Ambulatory surgical centers and neuro interventional clinics often prioritize devices that optimize turnover, reduce anesthesia requirements, and simplify inventory, while diagnostic imaging centers and hospitals focus on integrated solutions that support complex case mixes and robust post-procedural monitoring. Understanding these segmentation interdependencies enables more precise targeting of clinical evidence generation, training programs, and commercial engagement models that resonate with specific procedural contexts and budgetary constraints.

How regional regulatory frameworks, clinical infrastructure maturity, and manufacturing ecosystems are shaping differentiated adoption patterns across major global markets

Regional dynamics exert substantial influence on device development, regulatory strategy, and clinical adoption patterns, with distinct market drivers apparent across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, robust acute stroke networks, advanced imaging infrastructure, and concentrated purchasing power among integrated health systems accelerate uptake of cutting-edge thrombectomy systems and flow diversion devices, while supply chain considerations and reimbursement environments shape procurement cycles and adoption pacing. Clinical research networks and registries in this region facilitate rapid evidence generation that supports iterative device improvements and guideline incorporation.

Europe, the Middle East & Africa present heterogeneous regulatory environments and reimbursement systems that require modular market entry strategies. Regulatory convergence across certain European jurisdictions simplifies some aspects of approval, but country-level reimbursement pathways and hospital procurement practices necessitate tailored value demonstration and local evidence generation. In parts of the Middle East and Africa, infrastructure constraints and workforce training needs influence the pace of adoption, creating opportunities for solutions that emphasize simplified workflows and robust clinical support.

Asia-Pacific is characterized by diverse adoption profiles driven by demographic trends, rising investment in stroke care pathways, and substantial manufacturing capacity. Several markets within the region present strong device manufacturing ecosystems and opportunities for collaborative innovation, while others prioritize cost-effective solutions compatible with constrained budgets. Across the region, rapid expansion of diagnostic imaging capabilities and growing emphasis on interventional neuroradiology training programs are important enablers of broader device utilization. Recognizing these regional distinctions is essential for designing regulatory strategies, clinical studies, and commercial partnerships that align with local system priorities.

Strategic corporate behaviors and competitive positioning that prioritize integrated platforms, evidence generation, and collaborative commercialization to drive durable clinical adoption

Competitive dynamics in interventional neurology are defined by a combination of sustained investment in R&D, strategic partnerships, and focused clinical engagement programs that drive product differentiation and platform evolution. Leading firms invest heavily to optimize device deliverability, material science, and platform interoperability, while pursuing targeted clinical studies and real-world evidence initiatives to substantiate performance claims. Collaborations with academic centers and neurovascular registries provide pivotal data that inform label expansions and guideline recognition, reinforcing clinician confidence and hospital purchasing committees' assessments.

In addition to organic product development, companies are actively pursuing portfolio rationalization and selective acquisitions to fill technology gaps-particularly where ancillary systems such as guidewires, microcatheters, and aspiration platforms create integrated solution opportunities. Distribution strategies are evolving to include direct engagement with large health systems, partnerships with specialist distributors for regional reach, and the development of training and proctoring programs to accelerate adoption. Service offerings that combine device supply with digital procedural analytics, long-term follow-up tools, and education pathways are emerging as differentiators that enhance provider loyalty and facilitate broader clinical uptake.

Finally, firms that demonstrate agility in responding to supply chain pressures, regulatory changes, and reimbursement complexity gain competitive advantage. Those that invest in transparent outcomes reporting and payer-engaged value frameworks position themselves to navigate pricing pressures and procurement scrutiny more effectively, while simultaneously reinforcing clinical credibility through sustained engagement with key opinion leaders and multidisciplinary treatment teams.

Practical and prioritized recommendations for manufacturers, health systems, and clinical leaders to align evidence, supply resilience, and commercialization for sustainable adoption

Industry leaders should prioritize a set of actionable initiatives that align product development, commercial engagement, and operational resilience with evolving clinical and policy realities. First, invest in robust clinical evidence programs that move beyond acute procedural metrics to encompass longitudinal outcomes, patient-reported measures, and health economics analyses that resonate with hospital procurement and payer decision-makers. Complement clinical trials with pragmatic registry data and real-world performance reporting to accelerate guideline inclusion and payer recognition.

Second, strengthen supply chain resilience by diversifying suppliers, implementing dual-sourcing strategies for critical components, and evaluating selective nearshoring opportunities to mitigate tariff and trade volatility. Establish clear inventory governance and collaborative forecasting arrangements with major health system customers to reduce lead-time risk. Third, design commercialization models that offer modular value propositions tailored to specific end users: packaged clinical support and training for ambulatory surgical centers, integrated platform solutions for high-volume hospitals, and targeted outreach for diagnostic imaging centers that support multidisciplinary workflows.

Fourth, prioritize interoperability and ease of use by harmonizing device interfaces with common imaging and navigation systems, while investing in digital support tools that enhance procedural planning and post-procedural follow-up. Finally, cultivate payer engagement strategies that emphasize outcomes-based approaches and total cost of care benefits, enabling negotiations that reflect device value in clinical pathways and support sustainable adoption across diverse healthcare settings.

A mixed-methods research framework combining primary clinician and procurement insights with systematic secondary analysis to ensure robust, reproducible conclusions

This research synthesizes multiple evidence streams to construct a comprehensive view of the interventional neurology device environment, leveraging a mixed-methods approach centered on primary stakeholder engagement and rigorous secondary analysis. Primary inputs include structured interviews with clinical thought leaders, interventionalists, hospital procurement executives, and device development experts to capture firsthand perspectives on procedural trends, device performance expectations, and institutional priorities. These qualitative engagements are supplemented by anonymized survey data from procedural teams to validate patterns of device selection and usage dynamics across different care settings.

Secondary research incorporates systematic review of peer-reviewed clinical literature, procedural registries, regulatory filings, and publicly available health system procurement documentation to ensure findings are grounded in documented clinical outcomes and policy contexts. Supply chain mapping and component sourcing analysis are conducted through supplier interviews and customs data review to identify exposure points and mitigation strategies. Triangulation across information sources is used to reconcile inconsistencies and strengthen confidence in thematic conclusions. Where appropriate, sensitivity analyses and scenario planning exercises are employed to explore the operational implications of policy shifts and technology adoption pathways.

Ethical standards and data privacy considerations governed the study's primary research activities, ensuring that interview and survey participants provided consent and that data were anonymized prior to analysis. The methodology emphasizes transparency and reproducibility by documenting data sources, interview protocols, and analytical frameworks available within the technical appendix for purchaser review.

A concise synthesis of clinical, operational, and policy dynamics that underscores the integrated priorities for advancing device adoption and sustaining clinical impact

In conclusion, interventional neurology devices occupy a rapidly evolving nexus of clinical innovation, supply chain complexity, and shifting care-delivery models that together dictate strategic priorities for manufacturers, providers, and payers. The trajectory of device development-from embolic agents and coil materials to advanced flow diversion platforms and thrombectomy systems-illustrates how material science, device engineering, and procedural technique co-evolve to improve patient outcomes. At the same time, trade policy dynamics and tariff-related pressures underscore the importance of resilient sourcing strategies and flexible commercial arrangements.

Strategic success in this environment depends on integrating rigorous clinical evidence generation with pragmatic supply chain planning and tailored commercialization approaches that respect the heterogeneity of end-user settings. Regional nuances in regulatory regimes, infrastructure maturity, and manufacturing capacity require bespoke market-entry and clinical engagement plans. Ultimately, stakeholders that align product innovation with demonstrable outcomes, transparent value propositions, and operational reliability will be best positioned to support clinicians in delivering advanced neurovascular care while navigating economic and policy headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Interventional Neurology Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Microspheres
    • 8.1.3. Particulate Embolics
  • 8.2. Flow Diversion Devices
    • 8.2.1. Fred
    • 8.2.2. Pipeline Devices
    • 8.2.3. Surpass Streamlines
  • 8.3. Neurovascular Coils
    • 8.3.1. Bioactive Coils
    • 8.3.2. Hydrogel Coils
    • 8.3.3. Platinum Coils
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Thrombectomy Devices
    • 8.5.1. Aspiration Catheters
    • 8.5.2. Stent Retrievers

9. Interventional Neurology Devices Market, by Technology

  • 9.1. Guidewire Systems
    • 9.1.1. Hydrophilic Coated
    • 9.1.2. Polymer Coated
  • 9.2. Mechanical Thrombectomy
  • 9.3. Microcatheter Systems
    • 9.3.1. Over The Wire Microcatheters
    • 9.3.2. Rapid Exchange Microcatheters
  • 9.4. Thrombolytic Agents
    • 9.4.1. Tpa
    • 9.4.2. Urokinase

10. Interventional Neurology Devices Market, by Application

  • 10.1. Aneurysm
  • 10.2. Arteriovenous Malformations
  • 10.3. Carotid Stenosis
  • 10.4. Ischemic Stroke
  • 10.5. Vasospasm

11. Interventional Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospital
  • 11.4. Neuro Interventional Clinics

12. Interventional Neurology Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Interventional Neurology Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Interventional Neurology Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Interventional Neurology Devices Market

16. China Interventional Neurology Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acandis GmbH
  • 17.7. B. Braun Melsungen AG
  • 17.8. Balt USA LLC
  • 17.9. Boston Scientific Corporation
  • 17.10. Cerus Endovascular Ltd.
  • 17.11. Integer Holdings Corporation
  • 17.12. Integra LifeSciences Holdings Corporation
  • 17.13. Johnson & Johnson Services, Inc.
  • 17.14. Medos SA
  • 17.15. Medtronic plc
  • 17.16. Merit Medical Systems, Inc.
  • 17.17. MicroPort Scientific Corporation
  • 17.18. MicroVention, Inc.
  • 17.19. Penumbra, Inc.
  • 17.20. Rapid Medical
  • 17.21. Stryker Corporation
  • 17.22. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. G7 INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)